Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab

The addition of pertuzumab (P) to trastuzumab (H) and neoadjuvant chemotherapy (NAC) has decreased the risk of distant recurrence in early stage HER2-positive breast cancer. The incidence of brain metastases (BM) in patients who achieved pathological complete response (pCR) versus those who do not i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferraro, Emanuela, Singh, Jasmeet, Patil, Sujata, Razavi, Pedram, Modi, Shanu, Chandarlapaty, Sarat, Barrio, Andrea V., Malani, Rachna, Mellinghoff, Ingo K., Boire, Adrienne, Wen, Hannah Y., Brogi, Edi, Seidman, Andrew D., Norton, Larry, Robson, Mark E., Dang, Chau T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940915/
https://www.ncbi.nlm.nih.gov/pubmed/35319017
http://dx.doi.org/10.1038/s41523-022-00380-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940915/
https://www.ncbi.nlm.nih.gov/pubmed/35319017
http://dx.doi.org/10.1038/s41523-022-00380-7

Ejemplares similares